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SCIENTIFIC DESIGN

INTRODUCTION
•
•
•
•
•
•

Parkinson's is a neurodegenerative disorder that causes damage
to dopaminergic neurons in the brain that are essential for
planning and controlling body movement
More than 10 million people are living with this disease in the
United States and there are 5,000 new cases diagnosed each
year
Motor symptoms and non-motor symptoms
Pramipexole is a type of dopamine agonist that mimics
dopamine effects. It was found to reduce the progressive loss of
striatal dopamine neuronal function.2
Carbidopa-levodopa has been known to wear off because
levodopa becomes less stable.1
One study showed that Levodopa had a lower rate of
neurodegeneration than the placebo group.3

Sample
Collection

Data
Collection

• Animal model: transgenic mice
• Control group and 3 different treatment groups
• Pramipexole
• Carbidopa-levodopa
• Both drugs

• Unified Parkinson Disease Rating Scale
(UPDRS)
• Dopamine transporter imaging using singlephoton emission computed tomography (SPECT)
with 2𝛽𝛽-carboxymethoxy-3𝛽𝛽(4-idodophenyl)
tropane (𝛽𝛽-CIT) labeled with iodine 123
• Compare clinical severity of disease and rates of
dopamine neuron degeneration

POTENTIAL CONCLUSIONS
•
•
•
•

Higher rate of success using Pramipexole
Higher rate of success using Carbidopa-levodopa
Both have the same effects of treating the symptoms of Parkinson’s
Long term solution for treating symptoms of Parkinson’s disease

Figure 1. Neuroimaging of the Rate of Loss of Striatal 𝜷𝜷-CIT Uptake.2
𝛽𝛽 –CIT SPECT is a biomarker for striatal dopamine neuron terminals.

Figure 3. The Progression of Loss of Neurons in Parkinson's.
Figure 2. The Total Scores on the Unified Parkinson’s Disease Rating
Scale (UPDRS).3

The cause of Parkinson's is unknown and there is currently no
cure.

POTENTIAL PITFALLS
• Higher doses of Levodopa can make patients develop Dyskinesia
(abnormal involuntary movements such as head bobbing, fidgeting,
swaying)
• Error in neuroimaging equipment

SPECIFIC AIM

This study aims to identify the effects of using Pramipexole and
Carbidopa-levodopa on blocking the activity of the mutated gene
LRRK2 which is known to result in the loss of dopaminergic
neurons in Parkinson's.
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